{ "schemaVersion": 2, "eyebrow": "Medical Toxicology", "title": "Acetaminophen Toxicity", "summary": "Acetaminophen toxicity requires rapid exposure clarification, timed serum concentration testing, early antidotal therapy when risk cannot be excluded, and escalation for evolving hepatic failure. This review emphasizes actionable diagnostic limits and the evidence gaps within the supplied sources.", "seoDescription": "Physician guide to acetaminophen toxicity assessment, limits of available evidence, and immediate management priorities for suspected overdose.", "clinicalQuestion": "How should physicians assess and manage suspected acetaminophen toxicity when exposure history or liver injury is uncertain?", "specialty": "Medical Toxicology", "audience": "U.S. physicians and medical trainees", "tags": [ "acetaminophen toxicity", "acetaminophen overdose", "acute liver failure", "drug-induced liver injury", "poison control" ], "keyTakeaways": [ "The supplied search results do not include an acetaminophen-specific guideline, antidote labeling, treatment nomogram, or validated treatment thresholds; do not infer dosing or escalation criteria from unrelated toxicology sources.", "For suspected poisoning, early toxicology or poison-center consultation is a high-value step; available poisoning references specifically endorse early poison-center or toxicologist involvement for salicylate toxicity and emphasize toxin-specific management decisions based on clinical status and laboratory findings.[17]", "Medication-related hepatotoxicity can be clinically silent initially; treatment decisions in acetaminophen overdose require agent-specific evidence that is not present in the supplied results." ], "sections": [ { "id": "evidence-limitations", "eyebrow": "Evidence boundary", "heading": "What the supplied evidence can and cannot support", "intro": "The search set contains no acetaminophen-specific management source.", "paragraphs": [ "No supplied result provides the standard elements needed for an evidence-grounded acetaminophen toxicity protocol: a timed acetaminophen concentration interpretation tool, N-acetylcysteine indications or dosing, criteria for extended antidote therapy, hepatic-failure transfer thresholds, or liver-transplant prognostication. Therefore, specific diagnostic thresholds, antidote regimens, and disposition recommendations cannot be stated without inventing evidence.", "The available toxicology references support general principles only. Salicylate poisoning guidance emphasizes that poisoning management is directed by clinical presentation, toxin concentration, and acid-base status, and recommends early poison-center or toxicologist consultation.[17] Carbon monoxide poisoning guidance similarly centers management on exposure history, compatible clinical findings, and toxin-specific testing.[16] These principles support prompt, structured evaluation of suspected acetaminophen poisoning but cannot substitute for acetaminophen-specific pathways." ], "bullets": [ "Do not apply salicylate ingestion thresholds, urinary alkalinization, or hemodialysis criteria to acetaminophen exposure.[17]", "Do not extrapolate treatment recommendations for carbon monoxide, lead, cocaine, snake envenomation, or immune-checkpoint toxicity to acetaminophen poisoning.[12][15][16][21]" ], "subsections": [], "table": { "caption": "Evidence available in the supplied results for suspected acetaminophen toxicity", "columns": [ "Clinical need", "Support in supplied sources", "Editorial implication" ], "rows": [ [ "Agent-specific antidote selection and dosing", "No acetaminophen-specific source supplied.", "Do not provide N-acetylcysteine dosing or route recommendations without an appropriate source." ], [ "Exposure-based treatment threshold", "No acetaminophen concentration nomogram or threshold supplied.", "Obtain and use a current acetaminophen-specific toxicology protocol; do not derive thresholds from other poisoning syndromes." ], [ "Role of toxicology consultation", "Early poison-center or toxicologist consultation is recommended in the supplied salicylate poisoning reference.[17]", "Consult regional poison control or a medical toxicologist promptly for suspected clinically significant overdose." ] ] } }, { "id": "initial-clinical-approach", "eyebrow": "Immediate actions", "heading": "Initial assessment should identify time-critical uncertainty", "intro": "Use a toxin-specific evaluation pathway while stabilizing the patient.", "paragraphs": [ "In suspected acetaminophen toxicity, the immediate clinical task is to determine whether exposure is acute, repeated supratherapeutic, extended-release, or temporally uncertain; whether there are coingestants; and whether hepatic injury or acute liver failure may already be present. The supplied evidence does not validate a particular history template, laboratory sequence, or threshold for acetaminophen, but poisoning references consistently frame management around exposure history, compatible clinical findings, and targeted laboratory testing.[16][17]", "Patients with altered mental status, hemodynamic instability, severe metabolic disturbance, gastrointestinal bleeding, or evidence of hepatic decompensation require resuscitation and an urgent toxicology-directed pathway. Serious poisoning syndromes may deteriorate rapidly; available poisoning guidance emphasizes early specialist input and supportive management while definitive toxin-specific therapy is organized.[16][17]" ], "bullets": [ "Stabilize airway, breathing, circulation, glucose, temperature, and seizures if present; supportive care is a core element of severe poisoning management.[16][17]", "Document product formulation, strength, number of units, timing, chronicity, intent, coingestants, alcohol exposure, fasting or malnutrition history, and use of combination products; these details determine the need for agent-specific interpretation, although the supplied sources do not provide acetaminophen-specific risk coefficients.", "Contact poison control or a medical toxicologist early rather than waiting for evolving hepatic abnormalities.[17]" ], "subsections": [], "table": { "caption": "High-yield information to obtain in suspected ingestion", "columns": [ "Domain", "Information needed now", "Why it changes next steps" ], "rows": [ [ "Exposure chronology", "Single versus repeated exposure; earliest and latest possible ingestion time; formulation and amount.", "Interpretation of toxin levels and antidotal decisions is time-dependent, but the acetaminophen-specific framework is not supplied." ], [ "Clinical severity", "Mental status, vital signs, vomiting, abdominal pain, jaundice, bleeding, hypoglycemia, and signs of organ failure.", "Identifies need for resuscitation, critical care, and urgent consultation; severe poisoning can require intensive supportive care.[16][17]" ], [ "Coexposures", "Alcohol, sedatives, opioids, salicylates, and other prescription or nonprescription products.", "Coingestants may alter presentation and mandate separate diagnostic or treatment pathways.[17]" ], [ "Medication reconciliation", "All acetaminophen-containing prescription and over-the-counter products.", "Prevents underrecognition of cumulative exposure; no dose threshold can be stated from the supplied evidence." ] ] } }, { "id": "testing-and-monitoring", "eyebrow": "Testing", "heading": "Order targeted studies, but use current acetaminophen-specific interpretation", "intro": "The supplied evidence supports testing principles, not acetaminophen thresholds.", "paragraphs": [ "Obtain a serum acetaminophen concentration and hepatic, renal, metabolic, and coagulation assessment according to current local toxicology practice. However, the supplied search results do not specify when to sample acetaminophen concentrations, how to interpret concentrations in early or delayed presentation, or which laboratory values trigger antidotal therapy. A concentration without reliable timing should be interpreted with toxicology support rather than by applying an unsourced rule.", "Serial evaluation is appropriate when ingestion timing is uncertain, when absorption may be delayed, or when there is suspected evolving organ injury; this is a general poisoning-management principle. Available sources illustrate that clinical trajectory and repeated laboratory assessment can direct management in poisoning, while recognizing that each toxin has distinct laboratory and treatment logic.[16][17]" ], "bullets": [ "Use laboratory testing to define current organ dysfunction and to trend deterioration; do not use unrelated FDA adverse-event grading scales as clinical treatment thresholds for overdose.[1][13]", "Interpret aminotransferase elevation in clinical context. Drug labels demonstrate that medication-associated hepatic injury can range from asymptomatic transaminase elevation to severe hepatic injury, but these data are not acetaminophen-specific.[2][3][7][9]", "If liver injury is present, investigate competing causes while treating suspected acetaminophen exposure under toxicology guidance; immune-checkpoint hepatitis guidance likewise emphasizes exclusion of viral infection, alcohol, other drugs, and disease progression in suspected drug-related liver injury.[13]" ], "subsections": [], "table": { "caption": "Testing domains in suspected acetaminophen toxicity", "columns": [ "Domain", "Purpose", "Evidence limitation" ], "rows": [ [ "Serum acetaminophen concentration", "Quantifies exposure and informs toxin-specific risk assessment.", "No timing requirement, concentration threshold, or nomogram is available in the supplied sources." ], [ "Hepatic assessment", "Detects and trends hepatocellular injury and synthetic dysfunction.", "The supplied results recognize drug-associated hepatotoxicity but provide no acetaminophen-specific action thresholds.[2][3][7][9]" ], [ "Renal and metabolic assessment", "Identifies organ dysfunction and physiologic complications requiring supportive care.", "No acetaminophen-specific monitoring frequency or escalation trigger is supplied." ], [ "Coingestant testing", "Addresses alternate or additional toxidromes.", "Salicylate toxicity should be considered with unexplained acid-base disturbance and managed through toxin-specific consultation.[17]" ] ] } }, { "id": "management-priorities", "eyebrow": "Management", "heading": "Use definitive acetaminophen guidance rather than generic toxicity extrapolation", "intro": "Antidotal treatment details require sources absent from this search set.", "paragraphs": [ "The standard definitive therapy for acetaminophen poisoning cannot be detailed here because no supplied source addresses N-acetylcysteine. It would be unsafe to supply dosing, treatment duration, stopping criteria, or use in pregnancy, renal impairment, delayed presentation, or acute liver failure without a current acetaminophen-specific guideline or FDA label.", "Until definitive guidance is obtained, management should prioritize resuscitation, early toxicology consultation, confirmation of exposure chronology, serial organ-function assessment, and transfer to a center capable of critical care and hepatology support when substantial hepatic injury or organ failure is suspected. This is consistent with the general principle that severe poisoning requires supportive care and early specialty input.[16][17]" ], "bullets": [ "Do not delay poison-center consultation while awaiting all laboratory results when clinically significant overdose is possible.[17]", "Avoid assuming that a normal initial clinical examination excludes serious poisoning; early symptoms may be nonspecific in toxic exposures.[16][17]", "Do not use animal toxicology data to determine bedside safety or treatment thresholds; animal studies have limited ability to predict human toxicity, particularly negative findings used to exclude harm.[20]" ], "subsections": [], "table": { "caption": "Management decisions requiring an acetaminophen-specific source", "columns": [ "Decision", "Why it is high stakes", "What to do with current evidence set" ], "rows": [ [ "When to start N-acetylcysteine", "Delayed or omitted antidotal therapy may permit preventable hepatic injury.", "Use regional poison-center or medical-toxicology guidance; no regimen is supported by supplied results." ], [ "When to repeat serum acetaminophen testing", "Interpretation depends on formulation, timing, and absorption context.", "Follow an acetaminophen-specific protocol rather than an inferred interval." ], [ "When to stop antidotal therapy", "Requires integrated exposure and liver-injury criteria.", "Do not specify without current toxin-specific guidance." ], [ "When to transfer for liver-failure care", "Requires validated prognostic criteria and center-specific capabilities.", "Escalate early with toxicology, critical care, and hepatology input if organ failure is suspected." ] ] } }, { "id": "special-populations-and-prevention", "eyebrow": "Prevention", "heading": "Prevent recurrent exposure through medication reconciliation and systems review", "intro": "Combination products and repeated use create avoidable uncertainty.", "paragraphs": [ "For nonintentional exposures, reconcile all prescription, over-the-counter, and combination analgesic or cold products at discharge and during follow-up. This is a practical safety intervention, but the supplied search results do not provide an acetaminophen-specific maximum daily dose or risk threshold. Physicians should therefore communicate a product-specific plan based on current labeling and poison-center advice.", "For intentional ingestion, incorporate psychiatric assessment and lethal-means safety planning after medical stabilization. The supplied evidence does not address acetaminophen-specific psychiatric disposition criteria; decisions should follow local emergency psychiatry standards and the patient’s suicide-risk assessment." ], "bullets": [ "Specify one prescriber or pharmacist responsible for reviewing total acetaminophen exposure across products.", "Document the product formulation and exposure estimate in the discharge record to support follow-up and prevent duplicate treatment.", "Advise patients to seek immediate care rather than self-monitor after suspected overdose or uncertain cumulative exposure; poisoning references emphasize urgent evaluation for suspected toxic exposure.[16][17]" ], "subsections": [], "table": { "caption": "Prevention targets after suspected toxicity", "columns": [ "Target", "Action" ], "rows": [ [ "Duplicate exposure", "Reconcile all acetaminophen-containing products; provide a written medication list." ], [ "Intentional self-harm recurrence", "Complete psychiatric risk assessment and safety planning after medical stabilization." ], [ "Fragmented follow-up", "Communicate toxicology recommendations, laboratory trajectory, and follow-up testing plan to outpatient clinicians." ] ] } } ], "faq": [ { "question": "Can this article provide a N-acetylcysteine regimen?", "answer": "No. None of the supplied sources contains acetaminophen-specific N-acetylcysteine dosing, route selection, duration, or stopping criteria. Use current poison-center, toxicology, or institutional acetaminophen guidance." }, { "question": "Should a normal initial examination reassure clinicians after suspected acetaminophen overdose?", "answer": "No. Toxic exposures can have nonspecific early symptoms, and management should be based on exposure history, targeted testing, and clinical trajectory with early toxicology input.[16][17]" }, { "question": "What is the highest-value immediate consultation?", "answer": "Contact regional poison control or a medical toxicologist early. The supplied salicylate poisoning reference specifically recommends early poison-center or toxicologist consultation, a generalizable process principle for potentially serious overdose.[17]" } ], "references": [ { "number": 1, "title": "Guidance for Industry: Toxicity Grading Scale for Healthy ...", "detail": "www.fda.gov", "url": "https://www.fda.gov/media/73679/download", "authors": "www.fda.gov", "host": "www.fda.gov" }, { "number": 2, "title": "[PDF] 4215606 This label may not be the latest approved by FDA. For ...", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021162s040lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 3, "title": "This label may not be the latest approved by FDA. For current ...", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021162s045lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 4, "title": "highlights of prescribing information", "detail": "dailymed.nlm.nih.gov", "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fc439ae8-a79e-4942-8d02-22422b19b015&type=display", "authors": "dailymed.nlm.nih.gov", "host": "dailymed.nlm.nih.gov" }, { "number": 5, "title": "[PDF] FULL PRESCRIBING INFORMATION - accessdata.fda.gov", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204994Orig1s000lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 6, "title": "FDA Fda", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020711s045s046s047lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 7, "title": "These highlights do not include all the information needed to use MERCAPTOPURINE safely and effectively. See full prescribing information for MERCAPTOPURINE.\n MERCAPTOPURINE oral suspension\n Initial U.S. Approval: 1953", "detail": "dailymed.nlm.nih.gov", "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9c6fc66b-522f-499d-961a-cde6ca0ec2e5&type=display", "authors": "dailymed.nlm.nih.gov", "host": "dailymed.nlm.nih.gov" }, { "number": 8, "title": "FDA approves givosiran for acute hepatic porphyria | FDA", "detail": "www.fda.gov", "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-givosiran-acute-hepatic-porphyria", "authors": "www.fda.gov", "host": "www.fda.gov" }, { "number": 9, "title": "These highlights do not include all the information needed to use meloxicam oral suspension safely and effectively. See full prescribing information for meloxicam oral suspension. \n Meloxicam oral suspension Initial U.S. Approval: 2004", "detail": "dailymed.nlm.nih.gov", "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=55af77dd-2abc-49a6-990c-399d5a5e7a91", "authors": "dailymed.nlm.nih.gov", "host": "dailymed.nlm.nih.gov" }, { "number": 10, "title": "Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK", "detail": "www.bmj.com", "url": "https://www.bmj.com/content/381/bmj-2022-074678", "authors": "www.bmj.com", "host": "www.bmj.com" }, { "number": 11, "title": "Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation | RMD Open", "detail": "rmdopen.bmj.com", "url": "https://rmdopen.bmj.com/content/10/1/e003980", "authors": "rmdopen.bmj.com", "host": "rmdopen.bmj.com" }, { "number": 12, "title": "Lead toxicity - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/755", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com" }, { "number": 13, "title": "Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group | Journal for ImmunoTherapy of Cancer", "detail": "jitc.bmj.com", "url": "https://jitc.bmj.com/content/5/1/95", "authors": "jitc.bmj.com", "host": "jitc.bmj.com" }, { "number": 14, "title": "Piloting a new method to estimate action thresholds in ...", "detail": "ebm.bmj.com", "url": "https://ebm.bmj.com/content/ebmed/28/6/392.full.pdf", "authors": "ebm.bmj.com", "host": "ebm.bmj.com" }, { "number": 15, "title": "Cocaine toxicity - Symptoms, diagnosis and treatment", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-gb/340?locale=el", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com" }, { "number": 16, "title": "Carbon monoxide poisoning - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/432", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com" }, { "number": 17, "title": "Salicylate poisoning - Symptoms, diagnosis and treatment | BMJ Best Practice", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/1129", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com" }, { "number": 18, "title": "Early toxicity and clinical outcomes after chimeric antigen ...", "detail": "jitc.bmj.com", "url": "https://jitc.bmj.com/content/9/8/e002303", "authors": "jitc.bmj.com", "host": "jitc.bmj.com" }, { "number": 19, "title": "The serum digoxin test and digoxin toxicity: a Bayesian ...", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/10.1161/01.cir.64.2.409", "authors": "www.ahajournals.org", "host": "www.ahajournals.org" }, { "number": 20, "title": "Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Is it Time to Rethink Our Current Approach?", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacbts.2019.10.008", "authors": "www.jacc.org", "host": "www.jacc.org" }, { "number": 21, "title": "Wilderness Medical Society Practice Guidelines for the Treatment of Pitviper Envenomations in the United States and Canada", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1080603215002203", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 22, "title": "Revision of the ICH guideline on detection of toxicity to reproduction for medicinal products: SWOT analysis", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0890623816300491", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 23, "title": "Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/014067369392244N", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 24, "title": "[PDF] Guideline on Repeated Dose Toxicity", "detail": "www.ema.europa.eu", "url": "https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-repeated-dose-toxicity_en.pdf", "authors": "www.ema.europa.eu", "host": "www.ema.europa.eu" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "Guidance for Industry: Toxicity Grading Scale for Healthy ...", "detail": "www.fda.gov", "url": "https://www.fda.gov/media/73679/download", "authors": "www.fda.gov", "host": "www.fda.gov", "snippet": "Guidance for Industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials Additional copies of this guidance are available from the Office of Communication, Training and Manufacturers Assistance (HFM-40), 1401 Rockville Pike, Suite 200N, ", "score": 0.27818865 }, { "number": 2, "title": "[PDF] 4215606 This label may not be the latest approved by FDA. For ...", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021162s040lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "increased risk of renal impairment (7.3) • Dual blockade of renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7.4) • Antidiabetic drugs: Dosage adjustment may be required (7.6) • Cholestyramine and colestipol: Reduced absorption of thiazides (7.7) ---------", "score": 0.70067 }, { "number": 3, "title": "This label may not be the latest approved by FDA. For current ...", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021162s045lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "increased risk of renal impairment (7.3) • Dual blockade of renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7.4) • Antidiabetic drugs: Dosage adjustment may be required (7.6) • Cholestyramine and colestipol: Reduced absorption of thiazides (7.7) ---------", "score": 0.6844544 }, { "number": 4, "title": "highlights of prescribing information", "detail": "dailymed.nlm.nih.gov", "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fc439ae8-a79e-4942-8d02-22422b19b015&type=display", "authors": "dailymed.nlm.nih.gov", "host": "dailymed.nlm.nih.gov", "snippet": "USE IN SPECIFIC POPULATIONS In the presence of mild to moderate renal or hepatic impairment, adjustment of dosing is not required for treatment of gout flare, prophylaxis of gout flare and FMF, but patients should be monitored closely (8.6). In patients with severe renal impairment for prophylaxis", "score": 0.6501347 }, { "number": 5, "title": "[PDF] FULL PRESCRIBING INFORMATION - accessdata.fda.gov", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204994Orig1s000lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "of 100 mg to 200 mg twice daily (2.1) • Renal impairment: Dose adjustment is recommended for patients with severe renal impairment (creatinine clearance ≤ 30 mL/min) (2.3, 12.3) • Hepatic impairment: Dose adjustment is recommended for patients with mild or moderate hepatic impairment; use in severe ", "score": 0.63452125 }, { "number": 6, "title": "FDA Fda", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020711s045s046s047lbl.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "NTS is recommended. 2.6 Dose Adjustment in Patients with Hepatic Impairment In patients with moderate to severe hepatic impairment (Child-Pugh score: 7 to 15), the maximum dose should not exceed 150 mg every other day. In patients with mild hepatic impairment (Child-Pugh score: 5 to 6), consider red", "score": 0.6072213 }, { "number": 7, "title": "These highlights do not include all the information needed to use MERCAPTOPURINE safely and effectively. See full prescribing information for MERCAPTOPURINE.\n MERCAPTOPURINE oral suspension\n Initial U.S. Approval: 1953", "detail": "dailymed.nlm.nih.gov", "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9c6fc66b-522f-499d-961a-cde6ca0ec2e5&type=display", "authors": "dailymed.nlm.nih.gov", "host": "dailymed.nlm.nih.gov", "snippet": "## 2.3 Dosage Modifications in Renal and Hepatic Impairment\n\nRenal Impairment\n \nUse the lowest recommended starting dosage for MERCAPTOPURINE or increase the dosing interval to every 36 to 48 hours in patients with renal impairment (CLcr less than 50 mL/min). Adjust the dosage to maintain absolute ", "score": 0.46482924 }, { "number": 8, "title": "FDA approves givosiran for acute hepatic porphyria | FDA", "detail": "www.fda.gov", "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-givosiran-acute-hepatic-porphyria", "authors": "www.fda.gov", "host": "www.fda.gov", "snippet": "Title: FDA approves givosiran for acute hepatic porphyria | FDA\n**The .gov means it’s official.**. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The **https://** ensures that you are connecting to the offic", "score": 0.4051433 }, { "number": 9, "title": "These highlights do not include all the information needed to use meloxicam oral suspension safely and effectively. See full prescribing information for meloxicam oral suspension. \n Meloxicam oral suspension Initial U.S. Approval: 2004", "detail": "dailymed.nlm.nih.gov", "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=55af77dd-2abc-49a6-990c-399d5a5e7a91", "authors": "dailymed.nlm.nih.gov", "host": "dailymed.nlm.nih.gov", "snippet": "failure (5.5) Renal Toxicity: Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of meloxicam oral suspension in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function (5.", "score": 0.36127794 }, { "number": 10, "title": "Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK", "detail": "www.bmj.com", "url": "https://www.bmj.com/content/381/bmj-2022-074678", "authors": "www.bmj.com", "host": "www.bmj.com", "snippet": "The outcome of interest was methotrexate toxicity associated drug discontinuation, defined as a prescription gap of ≥90 days with either an abnormal blood test result or a diagnostic code for an abnormal blood test result within ±60 days of the last prescription date.17 The thresholds for abnormal b", "score": 0.61972505 }, { "number": 11, "title": "Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation | RMD Open", "detail": "rmdopen.bmj.com", "url": "https://rmdopen.bmj.com/content/10/1/e003980", "authors": "rmdopen.bmj.com", "host": "rmdopen.bmj.com", "snippet": "It is important to realise that DILI can be idiosyncratic and annual testing is unlikely to detect them early enough to improve patient outcome. It is beyond our remit to propose threshold at which the frequency of monitoring blood tests should be altered. These decisions are best taken by guideline", "score": 0.4785538 }, { "number": 12, "title": "Lead toxicity - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/755", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com", "snippet": "open menu\n\nWhen viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.\n\n# Lead toxicity\n\nEpidemiology\n\nEtiology\n\nCase history\n\nApproach\n\nHistory and exam\n\nTests\n\nDifferentials\n\nCriter", "score": 0.47738418 }, { "number": 13, "title": "Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group | Journal for ImmunoTherapy of Cancer", "detail": "jitc.bmj.com", "url": "https://jitc.bmj.com/content/5/1/95", "authors": "jitc.bmj.com", "host": "jitc.bmj.com", "snippet": "screening for endocrine abnormalities is not routinely performed (other than thyroid function tests, in some cases), and corticosteroids may be initiated empirically for suspected irAEs, which interferes with subsequent endocrine testing. A low threshold of clinical suspicion is therefore warranted ", "score": 0.25937325 }, { "number": 14, "title": "Piloting a new method to estimate action thresholds in ...", "detail": "ebm.bmj.com", "url": "https://ebm.bmj.com/content/ebmed/28/6/392.full.pdf", "authors": "ebm.bmj.com", "host": "ebm.bmj.com", "snippet": "Conversely, for ailments where the treatment is very toxic or otherwise imposes a serious burden on the patient, they want near 100% certainty to start treatment, for example, when chemotherapy in a patient with a suspicious lesion in the lung is being considered. In both cases, physicians will pres", "score": 0.21206917 }, { "number": 15, "title": "Cocaine toxicity - Symptoms, diagnosis and treatment", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-gb/340?locale=el", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com", "snippet": "Some patients may die suddenly before treatment is given. Presentation includes tachycardia, hypertension, hyperthermia, diaphoresis, mydriasis, and agitation.", "score": 0.13381115 }, { "number": 16, "title": "Carbon monoxide poisoning - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/432", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com", "snippet": "​ The binding of CO results in tissue hypoxia and impairment of cellular respiration, and direct effects of CO toxicity at the cellular level. CO poisoning can present in patients as a wide range of acute and chronic symptoms.(#referencePop1)Ashcroft J, Fraser E, Krishnamoorthy S, et al. Carbon mono", "score": 0.10821744 }, { "number": 17, "title": "Salicylate poisoning - Symptoms, diagnosis and treatment | BMJ Best Practice", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/1129", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com", "snippet": "Chronic poisoning tends to occur after repeated exposure to high-dose aspirin, particularly in people with renal insufficiency.(#referencePop1)Palmer BF, Clegg DJ. Salicylate toxicity. N Engl J Med. 2020 Jun 25;382(26):2544-55.\n\n### History and exam\n\n#### Key diagnostic factors\n\n#### Other diagnosti", "score": 0.0784517 }, { "number": 18, "title": "Early toxicity and clinical outcomes after chimeric antigen ...", "detail": "jitc.bmj.com", "url": "https://jitc.bmj.com/content/9/8/e002303", "authors": "jitc.bmj.com", "host": "jitc.bmj.com", "snippet": "by JE Brammer · 2021 · Cited by 71 — Multivariable regression was utilized to evaluate relationships between standard clinical and laboratory measures and disease outcomes.", "score": 0.07209274 }, { "number": 19, "title": "The serum digoxin test and digoxin toxicity: a Bayesian ...", "detail": "www.ahajournals.org", "url": "https://www.ahajournals.org/doi/10.1161/01.cir.64.2.409", "authors": "www.ahajournals.org", "host": "www.ahajournals.org", "snippet": "We describe a method that helps to clarify the role of the serum digoxin test in decreasing the uncertainty surrounding the diagnosis and treatment of toxicity.", "score": 0.12548296 }, { "number": 20, "title": "Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Is it Time to Rethink Our Current Approach?", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacbts.2019.10.008", "authors": "www.jacc.org", "host": "www.jacc.org", "snippet": "Open in ViewerImage 5\n\nFigure 3. Calculating LR\n\nThe likelihood that a test showing toxicity in a mouse predicts toxicity in the rat (positive likelihood ratio [PLR]) or that a test showing no toxicity in a mouse predicts nontoxicity in a rat (negative likelihood ratio [NLR]). M+R+=toxicity present ", "score": 0.108670644 }, { "number": 21, "title": "Wilderness Medical Society Practice Guidelines for the Treatment of Pitviper Envenomations in the United States and Canada", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1080603215002203", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "### Ann Emerg Med (2001) \n A.M. Ruha _et al._\n### Late hematologic toxicity following treatment of rattlesnake envenomation with Crotalidae polyvalent immune Fab antivenom\n\n### Toxicon (2011) \n M.E. Douglas _et al._\n### Phylogeography of the Western rattlesnake (_Crotalus viridis_) complex, with", "score": 0.374837 }, { "number": 22, "title": "Revision of the ICH guideline on detection of toxicity to reproduction for medicinal products: SWOT analysis", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0890623816300491", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "More than 20 years after taking effect, ICH S5 guideline is about to undergo its first major revision . This review uses a SWOT (strengths, weaknesses, opportunities and threats) analysis to identify and discuss salient points to be considered in the ICH S5 guideline revision.\n\n## Access through you", "score": 0.36514026 }, { "number": 23, "title": "Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/014067369392244N", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "# Articles Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Although interest in clinical guidelines has never been greater, uncertainty persists about whether they are effective. We have identified 59 published evaluations of clinical guidelines that m", "score": 0.19794047 }, { "number": 24, "title": "[PDF] Guideline on Repeated Dose Toxicity", "detail": "www.ema.europa.eu", "url": "https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-repeated-dose-toxicity_en.pdf", "authors": "www.ema.europa.eu", "host": "www.ema.europa.eu", "snippet": "repeated administration. This includes identification of potential target organs of toxicity and exposure/response relationships, and may include the potential reversibility of toxic effects. This information should be part of the safety assessment to support the conduct of human clinical trials and", "score": 0.41506538 } ], "publishedAt": "2026-08-20T23:52:53.644268Z", "updatedAt": "2026-08-20T23:52:53.644268Z", "readingMinutes": 4, "slug": "acetaminophen-toxicity" }